SubsidieMeesters logoSubsidieMeesters
ProjectenRegelingenAnalyses

Direct in utero engineering of mouse models

The LIMITLESS project aims to develop a whole-embryo gene editing technology for in utero manipulation, enhancing life sciences research while reducing ethical and financial burdens of mouse models.

Subsidie
€ 2.265.000
2025

Projectdetails

Introduction

Mouse models are a gold standard for life sciences research, spanning developmental biology, cancer studies, and pre-clinical testing, but they also have important limitations. Mouse colony maintenance is expensive, and the large colonies needed are ethically problematic.

Limitations of Mouse Models

Approaches aiming for cell-type specific manipulations can be confounded by:

  • Leaky promoters
  • Off-target/unknown promoter expression
  • Endogenous Cre sites
  • Cre toxicity

Finally, mouse strains generated in different inbred genetic backgrounds yield confounding results when interbred, or necessitate extensive back-crossing, which again leads to large usage of mice. An alternative strategy to generate mouse models, circumventing these issues, is direly needed.

NEPTUNE Technology

To solve this problem for the mouse nervous system, we previously developed neural plate targeting with in utero nano-injection (NEPTUNE). NEPTUNE targets 95% of cells in the brain, can recapitulate established mouse models, and can be used flexibly for cell-type specific manipulations.

LIMITLESS Project

In LIMITLESS, my lab will leverage our expertise in ultra-high titer viral production, developmental biology, and technology development to go beyond the state of the art and develop a technology for whole-embryo editing in utero. We will combine this technology with next generation single cell lineage tracing to resolve the “family tree” of all cell types in developing embryos, providing both fundamental new knowledge and information that is leverageable for further development of the technique.

Conclusion

In sum, my lab will develop a much-needed technology for whole embryo genetic manipulation, opening the door to limitless new types of experiments. Direct in utero whole-embryo gene editing would accelerate life sciences research, reduce the financial and ethical costs of animal work, and enable experiments currently beyond reach with existing technology.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.265.000
Totale projectbegroting€ 2.265.000

Tijdlijn

Startdatum1-5-2025
Einddatum30-4-2030
Subsidiejaar2025

Partners & Locaties

Projectpartners

  • KAROLINSKA INSTITUTETpenvoerder

Land(en)

Sweden

Inhoudsopgave

European Research Council

Financiering tot €10 miljoen voor baanbrekend frontier-onderzoek via ERC-grants (Starting, Consolidator, Advanced, Synergy, Proof of Concept).

Bekijk regeling

Vergelijkbare projecten binnen European Research Council

ProjectRegelingBedragJaarActie

Towards Artificial Human Embryoid Models: Engineered and Synthetic Platforms for Ex Utero Mammalian Embryogenesis

Develop biotechnological platforms to culture mammalian embryos ex utero and create synthetic embryoids for advancing stem cell research and disease modeling.

ERC Consolid...€ 2.000.000
2023
Details

Uncovering the role and regulation of 3D DNA-RNA nuclear dynamics in controlling cell fate decisions

This project aims to elucidate the interplay between 3D genome organization and transcriptome dynamics in early mouse embryos to identify factors influencing cell fate decisions.

ERC Starting...€ 1.500.000
2023
Details

In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain Diseases

This project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively.

ERC Consolid...€ 2.249.895
2022
Details

A sonogenetic brain-machine interface for neurosciences and visual restoration

Developing a novel sonogenetic brain-machine interface for remote, precise control of neuronal networks in large primate brains to advance treatments for neurological disorders.

ERC Synergy ...€ 7.817.939
2024
Details

Prime editing to Repair Inherited Metabolic Errors: in vivo gene correction for human genetic disease

Develop an in vivo prime editing therapy for methylmalonic acidemia to correct genetic mutations in the liver, aiming for safe, efficient, and personalized treatments before irreversible damage occurs.

ERC Starting...€ 1.499.968
2022
Details
ERC Consolid...

Towards Artificial Human Embryoid Models: Engineered and Synthetic Platforms for Ex Utero Mammalian Embryogenesis

Develop biotechnological platforms to culture mammalian embryos ex utero and create synthetic embryoids for advancing stem cell research and disease modeling.

ERC Consolidator Grant
€ 2.000.000
2023
Details
ERC Starting...

Uncovering the role and regulation of 3D DNA-RNA nuclear dynamics in controlling cell fate decisions

This project aims to elucidate the interplay between 3D genome organization and transcriptome dynamics in early mouse embryos to identify factors influencing cell fate decisions.

ERC Starting Grant
€ 1.500.000
2023
Details
ERC Consolid...

In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain Diseases

This project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively.

ERC Consolidator Grant
€ 2.249.895
2022
Details
ERC Synergy ...

A sonogenetic brain-machine interface for neurosciences and visual restoration

Developing a novel sonogenetic brain-machine interface for remote, precise control of neuronal networks in large primate brains to advance treatments for neurological disorders.

ERC Synergy Grant
€ 7.817.939
2024
Details
ERC Starting...

Prime editing to Repair Inherited Metabolic Errors: in vivo gene correction for human genetic disease

Develop an in vivo prime editing therapy for methylmalonic acidemia to correct genetic mutations in the liver, aiming for safe, efficient, and personalized treatments before irreversible damage occurs.

ERC Starting Grant
€ 1.499.968
2022
Details

Vergelijkbare projecten uit andere regelingen

ProjectRegelingBedragJaarActie

A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system

The NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases.

EIC Pathfinder€ 2.988.377
2023
Details

New Prime Editing and non-viral delivery strategies for Gene Therapy

This project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders.

EIC Pathfinder€ 4.406.097
2022
Details

IMPROVING THE EFFECTIVENESS AND SAFETY OF EPIGENETIC EDITING IN BRAIN REGENERATION

REGENERAR aims to develop a non-viral delivery system to reprogram glial cells into neurons for treating CNS injuries, focusing on safety, targeting, and stakeholder collaboration.

EIC Pathfinder€ 2.943.233
2024
Details
EIC Pathfinder

A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system

The NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases.

EIC Pathfinder
€ 2.988.377
2023
Details
EIC Pathfinder

New Prime Editing and non-viral delivery strategies for Gene Therapy

This project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders.

EIC Pathfinder
€ 4.406.097
2022
Details
EIC Pathfinder

IMPROVING THE EFFECTIVENESS AND SAFETY OF EPIGENETIC EDITING IN BRAIN REGENERATION

REGENERAR aims to develop a non-viral delivery system to reprogram glial cells into neurons for treating CNS injuries, focusing on safety, targeting, and stakeholder collaboration.

EIC Pathfinder
€ 2.943.233
2024
Details

SubsidieMeesters logoSubsidieMeesters

Vind en verken subsidieprojecten in Nederland en Europa.

Links

  • Projecten
  • Regelingen
  • Analyses

Suggesties

Heb je ideeën voor nieuwe features of verbeteringen?

Deel je suggestie
© 2025 SubsidieMeesters. Alle rechten voorbehouden.